enGene Holdings Inc Common Stock

Yahoo Finance • 6 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of enGene Therapeutics Inc. (“Engene” or the “Company”) (NASDAQ: ENGN).  Such investors are advised to contact Danielle Peyton at ne... Full story

Yahoo Finance • 9 days ago

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge

FCPM III Services B.V. disclosed a new position in Damora Therapeutics(NASDAQ:DMRA) as of March 31, 2026, acquiring 2,441,000 shares for an estimated $65.63 million based on quarterly average pricing. What happened According to a Securit... Full story

Yahoo Finance • 9 days ago

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean

On May 15, 2026, FCPM III Services B.V. reported a sale of 818,460 shares of Dyne Therapeutics(NASDAQ:DYN), an estimated $14.11 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story

Yahoo Finance • 29 days ago

Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the best performing healthcare stocks so far in 2026. Leerink Partners lifted the price target on Oruka Therapeutics, Inc. (NASDAQ:ORKA) to $120 from $109 on April 30, reaffirming an Outperf... Full story

Yahoo Finance • last month

Bristol-Myers Squibb Company (BMY): Favorite for Conservative Portfolios

We just covered the 14 Best Defensive Stocks to Invest In Now and Bristol-Myers Squibb Company (NYSE:BMY) ranks 5th on this list. Bristol-Myers Squibb Company (NYSE:BMY) remains a favorite for conservative portfolios due to its exceptiona... Full story

Yahoo Finance • 3 months ago

This Biotech Was Quietly Bought Before a $58 Per Share Takeout

On February 17, 2026, FCPM III Services B.V. disclosed a buy of 1,489,096 RAPT Therapeutics(NASDAQ:RAPT) shares, an estimated $46.24 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story

Yahoo Finance • 4 months ago

Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN)

We recently published an article titled 10 Best Low Volatility Canadian Stocks to Buy. On January 30, Jefferies initiated coverage of enGene Holdings Inc. (NASDAQ:ENGN) with a Buy rating and a $28 price target, highlighting the company’s... Full story

Yahoo Finance • 8 months ago

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H... Full story

Yahoo Finance • 9 months ago

EnGene Holdings Inc. Q3 Loss Increases, Misses Estimates

(RTTNews) - enGene Holdings Inc. (ENGN) announced Loss for its third quarter that increased from the same period last year and missed the Street estimates. The company's bottom line totaled -$28.99 million, or -$0.57 per share. This com... Full story

Yahoo Finance • 9 months ago

enGene Holdings Inc (NASDAQ:ENGN) Posts Wider-Than-Expected Q3 Loss as R&D Spending Doubles

enGene Holdings Inc (NASDAQ:ENGN [https://www.chartmill.com/stock/quote/ENGN]) reported its third quarter 2025 financial results, posting a net loss per share that came in wider than analyst expectations. The clinical-stage biotechnology c... Full story

Yahoo Finance • 10 months ago

Video Processing Platform Markets: Video Encoding & Transcoding, Video Management,Video Ingest & Capture, Video Delivery & Distribution, Video Editing & Enhancement - Global Forecast to 2030

Dublin, July 30, 2025 (GLOBE NEWSWIRE) -- The "Video Processing Platform Market by Offering (Video Encoding & Transcoding, Video Management), Content Type (VOD, Short Form Video), Application (Video Ingest & Capture, Video Delivery & Dis... Full story

Yahoo Finance • 11 months ago

FDA grants RMAT designation to enGene's bladder cancer therapy

BOSTON/MONTREAL - The U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to enGene Holdings Inc.’s (NASDAQ:ENGN) lead therapy for treating high-risk bladder cancer, the company announced... Full story

Yahoo Finance • 12 months ago

Engene stock maintains buy rating at H.C. Wainwright on LEGEND trial

H.C. Wainwright has reiterated a buy rating and $25.00 price target on Engene Holdings Inc. (NASDAQ:ENGN), citing progress in the company’s pivotal LEGEND trial for high-risk non-muscle invasive bladder cancer (NMIBC). Currently trading at... Full story

Yahoo Finance • last year

Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now?

We recently published a list of 13 Best Canadian Penny Stocks to Invest in Now In this article, we are going to take a look at where enGene Holdings Inc. (NASDAQ:ENGN) stands against other best Canadian penny stocks to invest in now. We d... Full story